Open Access

Pretreatment 18 F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma——a retrospective study

Contributed equally
Radiation Oncology201510:4

https://doi.org/10.1186/s13014-014-0268-5

Received: 7 October 2014

Accepted: 19 November 2014

Published: 8 January 2015

Abstract

Background

Intratumoural heterogeneity has been demonstrated to be a strong indicator of malignant transformation. Our study was to investigate pretreatment 18 F-FDG parameters, including 18 F-FDG based heterogeneity for predicting survival in patients with locally advanced nasopharyngeal carcinoma (NPC).

Methods

Forty newly diagnosed, biopsy-proven locally advanced NPC patients who underwent 18 F-FDG PET/CT were retrospectively included. The following PET parameters were assessed: maximum and mean standardised uptake value (SUVmax and SUVmean), metabolic tumour volume (MTV), total lesion glycolysis (TLG) and intratumoral heterogeneity index (HI). The previous parameters were recorded both for the primary tumor (-T) and neck lymph nodes (-N). The following endpoints were evaluated: local control (LC), progression-free survival (PFS) and overall survival (OS). The survival analyses were performed using the Kaplan–Meier method. Univariate analysis was performed using the log-rank test.

Results

Patients with a lower HI-T, SUVmax-T, SUVmean-T and TLG-T had significantly better 2-year LC. In predicting PFS, we found that both lower HI-T and HI-N had significantly better prognosis. However, the OS was only statistically associated with HI-T.

Conclusion

18 F-FDG based heterogeneity appears to be an potential predicator of patient survival after treatment.

Keywords

Nasopharyngeal carcinoma 18 F-FDG PET/CT Prognosis Heterogeneity

Background

Nasopharyngeal carcinoma (NPC) is unique in terms of epidemiology, pathogenesis, and physical history compared to the anatomically adjacent cancers of the head and neck area. It is etiologically associated with the Epstein-Barr virus, and shows an endemic distribution: incidence rates are highest in South-Eastern Asia, including Malaysia, Indonesia, Singapore and South-Eastern China, and as such is the sixth most common cancer among males in the region [1].

NPC is a very radiosensitive tumor [2]; in addition, concurrent chemoradiation (CCRT) and induction chemotherapy (Chemo) have been shown to improve tumor control and survival in patients with locally advanced NPC [3,4]. However, some patients may still develop locoregional and distant failure, thus requiring salvage or palliative therapy [5-7]. Although traditional prognostic factors may provide some useful clinical information, they cannot predict treatment outcome reliably. Therefore, substantial research efforts have focused on the identification of novel prognostic factors to further stratify risk groups with the goal of developing individualized treatment strategies for these patients.

As a molecular imaging modality, 18 F-FDG PET/CT has been used in patients with NPC for the initial diagnosis and staging workup [8-10]. Several investigators have examined the value of 18 F-FDG PET functional parameters, such as maximum standard uptake value (SUVmax) and mean SUV (SUVmean) for predicting the prognosis of NPC [11-13]. Recently, other semi-quantitative parameters, for instance, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are becoming a topic of interest in cancer research. Some studies showed that MTV and TLG are important independent risk factors in primary NPC patients [14-17]. However, these parameters have not been sufficiently evaluated because they yielded conflicting results.

Intratumoural heterogeneity has been demonstrated to be a strong indicator of malignant transformation, and one might hypothesize that the texture of intratumoural tracer uptake on PET may represent a likewise useful parameter [18]. Therefore, our study was aimed to investigate 18 F-FDG parameters, including 18 F-FDG based heterogeneity for predicting survival in patients with locally advanced NPC.

Materials and methods

Patient Selection

Forty consecutive patients with newly diagnosed (the interval between date of diagnose and FDG scan date was about 1 week), biopsy-proven locally advanced NPC referred to our center between November 2006 and December 2011 for whole-body 18 F-FDG PET/CT were retrospectively included. Patients with metastatic disease at presentation (M1 stage), with other malignancies, or who had been previously treated at other institutions were excluded. All patients were staged according to 2010 American Joint Committee on Cancer staging system.

Pretreatment evaluation was composed of whole-body 18 F-FDG PET/CT, and routine procedures including complete medical history, physical examination, indirect or fiberoptic endoscopic examination of nasopharynx, biopsy of the neoplasm in nasopharynx, head and neck Magnetic Resonance Imaging (MRI) scans. These examinations were performed within 2 weeks before treatment. Our study need not get an approval from the review board because it was only a retrospective study. However, PET/CT is not covered by insurance in China, and informed written consent was obtained from our patients before examination.

PET/CT imaging

18 F-FDG was produced automatically by cyclotron (Siemens CTI RDS Eclips ST, Knoxville, Tennessee, USA) using Explora FDG4 module in our center. Radiochemical purity was over 95%.

Before the 18 F-FDG PET/CT, all the patients were requested to fast at least 4 h. At the time of the tracer injection (dosage: 7.4 MBq/kg), the patients presented blood glucose level under 10 mmol/L. Before and after injection, patients were kept lying comfortably in a quiet, dimly lit room. Scanning was initiated 1 h after administration of the tracer. The images were obtained on a Siemens biograph 16HR PET/CT scanner (Knoxville, Tennessee, USA). The transaxial intrinsic spatial resolution was 4.1 mm (full-width at half-maximum) in the center of the field of view. The data acquisition procedure was as follows: CT scanning was first performed, from the proximal thighs to head, with 120 kV, 80 ~ 250 mA, pitch 3.6, rotation time 0.5. Immediately after CT scanning, a PET emission scan that covered the identical transverse field of view was obtained. Acquisition time was 2 ~ 3 min per table position. PET image data sets were reconstructed iteratively by applying the CT data for attenuation correction, and coregistered images were displayed on a workstation.

Imaging interpretation

A multimodality computer platform (Syngo, Siemens, Knoxville, Tennessee, USA) was used for image review and manipulation. Two experienced nuclear medicine physician evaluated the images independently. The reviewers reached a consensus in cases of discrepancy.

Quantification of glucose metabolic activity was obtained using the SUV normalized to body weight. The SUVmax and SUVmean for primary tumor (SUVmax-T, SUVmean-T) and neck lymph nodes (SUVmax-N, SUVmean-N) were calculated. Besides, glucose metabolic tumor volume (MTV) was also recorded. The boundaries were drawn large enough to include the primary tumor within the nasopharynx or neck lymph nodes in the axial, coronal, and sagittal PET images. To define the contouring margins around the target, we used an SUV of 2.5. The contour around the target lesion inside the boundaries was automatically produced and the voxels presenting SUV intensity of greater than 2.5 within the contouring margin were incorporated to define the MTV. The TLG was calculated according to the following formula: TLG = SUVmean × MTV. A quantitative measure of intratumoral heterogeneity, heterogeneity index (HI) was obtained by dividing SUVmax by SUVmean for primary lesion and nodal disease [18,19].

Treatment and follow-up

Primary curative treatment consisted of Chemo + radiotherapy (RT) or Chemo + CCRT, according to the tumor stage and other clinical characteristics. As for RT, all patients received Intensity-Modulated Radiation Therapy (IMRT) for a cumulative dose of 70.4Gy in 32 fractions. We used TPF protocol for Chemo, which consisted of docetaxel 75 mg/m2 IV on day 1, cisplatin 75 mg/m2 IV on day 1, and 5-Fu 500 mg/m2/d continuously IV on 1-5 day. With respect to CCRT, cisplatin 40 mg/m2 was used IV weekly during radiation. The treatment protocal was approved by the Nasopharygneal carcinoma multidisciplinary team in our hospital after discussion.

Patients were followed every 3 months in the first to second year, then every 6 months in the third to fifth year and once a year thereafter. In each visit, medical history, physical examination and nasopharyngoscopy were performed. Nasopharyngeal MRI was performed 3 months and 1 year after completion of radiotherapy, and every 6 months in the second to fifth year, and then yearly thereafter. The following tests were done at least every year: chest CT or X-ray, abdominal sonography, and bone scan when clinically indicated.

Distant metastasis was proven by clinical and radiologic evidence, and pathologic evidence if possible. For those without pathologic evidence and obvious clinical symptoms, radiologic evidence would play a more important role. If radiologic evidence was not strong enough to prove metastatic disease at primary diagnosis, then a metastatic lesion might be proven by its enlargement or regression during or after chemotherapy.

Statistical analysis

We identified progression disease (PD) according to RECIST1.1. The following endpoints were evaluated: local control (LC), progression-free survival (PFS) and overall survival (OS). The PFS duration was measured from the date of first scan to the date of disease progression or was censored at the last follow-up date. Survival was defined as the time between the date of diagnosis and the date of death or last follow-up. The optimal SUVmax cut-off value for each endpoint, which showed the best trade-off between sensitivity and specificity, was determined by receiver operating characteristic (ROC) analysis following the method of Metz [20]. The survival analyses were performed using the Kaplan–Meier method. Univariate analysis was performed using the log-rank test. Data was analyzed by SPSS 13.0 software. All analyses were two-sided. A p value less than 0.05 was taken to indicate a significant difference.

Results

Patient characteristics and treatment outcome

The demographics and clinical characteristics of the patients were showed in Table 1. In our study, the median follow-up period was 30.5 months (range from 24.0- to 68.0 months). At the end of follow-up, among the 40 patients, 35 patients were alive and 5 patients had died, 5 experienced local recurrences and distant metastases happened in 10 patients. Distant metastasis was the main treatment failure, and the common sites of distant failure were liver, lung and bone.
Table 1

Patient demographics and clinical characteristics

Demographic or clinical

No. of patients

%

Characteristic

(n = 40)

Age

Median

52.5

 
 

Range

28 ~ 70

 

Gender

Male

29

72.5

 

Female

11

27.5

Histology

Squamous cell carcinoma

8

20.0

 

Non-keratinizing carcinoma

32

80.0

T stage

3

25

62.5

 

4

15

37.5

N stage

0

4

10.0

 

1

10

25.0

 

2

17

42.5

 

3

9

22.5

Treatment modality

Chemo + RT

21

52.5

 

Chemo + CCRT

19

47.5

Chemo = induction chemotherapy, RT = radiotherapy, CCRT = concurrent chemoradiotherapy.

Univariate analysis

Univariate analysis of prognostic factors for 2-year LC, PFS and OS were summarized in Table 2. The optimal cut-off value of HI-T, SUVmax-T, SUVmean-T, MTV-T, TLG-T, HI-N, SUVmax-N, SUVmean-N, MTV-N and TLG-N, determined by ROC analysis, were 2.9, 15.6, 4.7, 28.9 ml, 249.1 g, 2.3, 7.6, 5.4, 11.1 ml and 80.4 g, respectively.
Table 2

General characteristic and results of the univariate analysis of risk factors associated with LC, PFS and OS

Parameters

No. of patients

LC

PFS

OS

2-year rate (%)

p

2-year rate (%)

p

2-year rate (%)

p

Age (year)

       

<53

20

95.0

0.782

80.0

0.634

95.0

0.776

≥53

20

94.7

 

70.0

 

95.0

 

Gender

       

Male

29

100.0

0.016

72.4

0.868

96.6

0.644

Female

11

81.8

 

81.8

 

90.9

 

Histology

       

Squamous cell carcinoma

8

87.5

0.685

75.0

0.863

87.5

0.212

Non-keratinizing carcinoma

32

96.8

 

75.0

 

96.9

 

T stage

       

3

26

96.2

0.276

73.1

0.592

96.2

0.721

4

14

92.3

 

78.6

 

92.9

 

N stage

       

0-2

31

93.4

0.239

77.4

0.811

93.5

0.734

3

9

100.0

 

66.7

 

100.0

 

Treatment modality

       

Chemo + RT

21

95.0

0.086

76.2

0.594

95.2

0.968

Chemo + CCRT

19

94.7

 

73.7

 

94.7

 

HI-T

       

<2.9

23

100.0

0.028

100.0

<0.0001

100.0

0.022

≥2.9

17

87.8

 

41.2

 

88.2

 

SUVmax-T

       

<15.6

29

100.0

0.001

72.4

0.933

96.6

0.641

≥15.6

11

81.8

 

81.8

 

90.9

 

SUVmean-T

       

<4.7

23

100.0

0.006

69.6

0.929

95.7

0.942

≥4.7

17

88.2

 

82.4

 

94.1

 

MTV-T (ml)

       

<28.9

13

100.0

0.111

76.9

0.684

100.0

0.848

≥28.9

27

92.4

 

74.1

 

92.6

 

TLG-T (g)

       

<249.1

27

100.0

0.006

74.1

0.976

96.3

0.898

≥249.1

13

84.6

 

76.9

 

92.3

 

HI-N

       

<2.3

26

92.3

0.500

84.6

0.009

96.2

0.411

≥2.3

14

100.0

 

57.1

 

92.9

 

SUVmax-N

       

<7.6

20

95.0

0.692

75.0

0.672

95.0

0.891

≥7.6

20

94.7

 

75.0

 

95.0

 

SUVmean-N

       

<5.4

30

93.3

0.232

76.7

0.634

96.7

0.088

≥5.4

10

100.0

 

70.0

 

90.0

 

MTV-N (ml)

       

<11.1

28

92.9

0.125

78.6

0.907

96.4

0.270

≥11.1

12

100.0

 

66.7

 

91.7

 

TLG-N (g)

       

<80.4

32

93.6

0.235

75.0

0.429

93.8

0.770

≥80.4

8

100.0

 

75.0

 

100.0

 
We first examined the significance of traditional prognostic factors in the entire study cohort. The results showed that only gender was significantly associated with LC. With regard to the PET parameters, patients with a lower HI-T, SUVmax-T, SUVmean-T and TLG-T had significantly better 2-year LC (Figure 1). In predicting PFS, we found that both lower HI-T and HI-N had significantly better prognosis (Figure 2). However, the OS was only statistically associated with HI-T (Figure 3).
Figure 1

The Kaplan–Meier curves for the LC of locally advanced NPC patients (A Gender; B HI-T; C SUVmax-T; D SUVmean-T; E TLG-T; p< 0.05).

Figure 2

The Kaplan–Meier curves for the PFS of locally advanced NPC patients (A HI-T;B HI-N; p< 0.05).

Figure 3

The Kaplan–Meier curve of different HI-T group for the OS of locally advanced NPC patients ( p= 0.022).

Discussion

Prognostic factors for malignant tumors have always been attracting a lot of attention, because such a result could allow therapy to be tailored to the characteristics of an individual patient [21,22]. However, modern cancer care is critically dependent on imaging technologies. As a molecular imaging technology, PET can provide information about the functional or metabolic characteristics of malignancies, tumor stage and therapeutical response, and tumor recurrence; whereas conventional imaging technologies predominantly assess anatomical or morphological features of the tumor including its size, density, shape and so on [23,24]. There have been researches indicating that 18 F-FDG PET may non-invasively predict tumor response to treatment and reflect biologic aggressiveness of tumor such as cell viability, proliferative activity, hypoxia, low apoptosis rate, and P53 over-expression in head and neck tumors [25].

Recently, PET-derived parameters, such as the SUV and MTV, have shown potential prognostic value for primary NPC in several reports [11-17]. But most of them only analyzed the predictive value of no more than two PET parameters, and always focused on traditional parameters. Additionally, the results were varied and controversial. Among them, the SUV was the most widely used predicator. Several investigations suggested SUV could be valuable in prognosis [11-14,17] while some studies showed its uselessness [15,16]. Besides, most previous studies failed to point out the definite pattern of treatment failure (for instance, local recurrence or distant metastasis) which PET parameters may predict, so the conclusions were not able to guide which kind of more aggressive treatment, such as additional boost dose or chemotherapy, should be used in patients of high-risk predicted by 18 F-FDG PET.

In our study, SUVmax-T and SUVmean-T was associated with LC with a cut-off value of 15.6 and 4.7, which was higher than previous studies (SUVmax ranged from 6.48 to 12.0) [11-14,17]. In view of our enrolled patients, who were all locally advanced NPC, we arbitarily considered that the higher SUVmax was attributed to higer staging (T3-4) with more aggressive potential.

Recent investigators demonstrated that MTV and TLG were better than SUV alone for predicting prognosis[14-17]. Furthemore, TLG would be expected to provide a better prognostic stratification than either MTV or SUV because it integrates both anatomic (tumour volume) and biological data (glucose metabolism) theoretically. Nevertheless, our study showed TLG was only valuable in LC; Therefore, whether TLG was better than SUV or MTV in predicting prognosis of NPC was still unclear.

It is recognized that malignant tumors exhibit intratumoral biological heterogeneity associated with cellular and molecular characteristics such as cellular proliferation, necrosis, fibrosis, differences in blood flow and angiogenesis, cellular metabolism, hypoxia and expression of specific receptors, some of which may be evident on histological analysis. Similarly, heterogeneity of 18 F-FDG uptake within tumors has been attributed to a number of factors including cellularity, proliferation, angiogenesis, necrosis and hypoxia, factors that independently have been associated with more aggressive behaviour, poorer response to treatment and worse prognosis [26].

Intratumoral heterogeneity in 18 F-FDG PET images has been evaluated using textural analysis [27-29], the coefficient of variance (COV) [30], cumulative SUV-volume histograms (CSH) [31], the area under the CSH (AUC–CSH) [30,32] and fractal analysis [33]. However, the methods mentioned above were too complex to be used in clinical application. Recently, a feasible quantitative measure of heterogeneity, HI, has been successfully applied [18,19]. HI was obtained by dividing SUVmax by SUVmean, which could be easily measured in practice. In our study, we found that both HI-T and HI-N could be potentially used in predicting survivals. The consequences indicated that we should pay more attention to the tumor with greater heterogeneity.

The Radiation Therapy Oncology Group has conducted a study of concurrent chemoradiotherapy followed by adjuvant chemotherapy with bevacizumab (RTOG 0615). The results indicated that the therapy is feasible and may delay the progression of subclinical distant disease [34]. Another phase II clinical trial of cetuximab with concurrent chemoradiotherapy in locoregionally advanced NPC also showed that the strategy is feasible and the preliminary rate was favorable comparing with historic data [35]. It is our opinion that more aggressive systematic treatment may be considered in the patients with high risk of treatment failure, which could be predicted by HI-T of FDG PET.

Of course, the present study had several limitations. The first was the retrospective nature of the study. Another limitation was the relatively small number of patients, which might have led to the selection bias. The third and the largest drawback was the low number of events.

Conclusion

Our preliminary study demonstrated that pretreatment 18 F-FDG based heterogeneity appears to be an potential predicator of locally advanced NPC patient for disease progression and overall survival after treatment. These findings provide additional evidence supporting the use of 18 F-FDG PET in the clinical management of patients with NPC.

Notes

Abbreviations

NPC: 

Nasopharyngeal carcinoma

SUV: 

Standardised uptake value

MTV: 

Metabolic tumour volume

TLG: 

Total lesion glycolysis

HI: 

Heterogeneity index

CCRT: 

Concurrent chemoradiation

Chemo: 

Chemotherapy

MRI: 

Magnetic Resonance Imaging

RT: 

Radiotherapy

IMRT: 

Intensity-Modulated Radiation Therapy

LC: 

Local control

PFS: 

Progression-free survival

OS: 

Overall survival

ROC: 

Receiver operating characteristic

COV: 

Coefficient of variance

CSH: 

Cumulative SUV-volume histograms

AUC–CSH: 

Area under the CSH

Declarations

Acknowledgements

We thank for the help of the members in the Nasopharygneal carcinoma multidisciplinary team, Shanghai Cancer Center, Fudan University, Shanghai, China.

The study was supported by Youth Foundation of Shanghai Municipal Health Bureau (No. 20124Y092).

Authors’ Affiliations

(1)
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center
(2)
Department of Radiation Oncology, Fudan University Shanghai Cancer Center
(3)
Center for Biomedical imaging, Fudan University
(4)
Department of Oncology, Shanghai Medical College, Fudan University

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedView ArticleGoogle Scholar
  2. Yi JL, Gao L, Huang XD, Li SY, Luo JW, Cai WM, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 2006;65:161–8.PubMedView ArticleGoogle Scholar
  3. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. MAC-NPC Collaborative Group: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56.PubMedView ArticleGoogle Scholar
  4. Lim AM, Corry J, Collins M, Peters L, Hicks RJ, D'Costa I, et al. A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. Oral Oncol. 2013;49:468–74.PubMedView ArticleGoogle Scholar
  5. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–54.PubMedView ArticleGoogle Scholar
  6. Chang KP, Hao SP, Tsang NM, Ueng SH. Salvage surgery for locally recurrent nasopharyngeal carcinoma-A 10-year experience. Otolaryngol Head Neck Surg. 2004;131:497–502.PubMedView ArticleGoogle Scholar
  7. Wei WI, Chan JY, Ng RW, Ho WK. Surgical salvage of persistent or recurrent nasopharyngeal carcinoma with maxillary swing approach - Critical appraisal after 2 decades. Head Neck. 2011;33:969–75.PubMedView ArticleGoogle Scholar
  8. Liu FY, Lin CY, Chang JT, Ng SH, Chin SC, Wang HM, et al. 18 F-FDG PET can replace conventional work-up in primary M staging of nonkeratinizing nasopharyngeal carcinoma. J Nucl Med. 2007;48:1614–9.PubMedView ArticleGoogle Scholar
  9. Liu FY, Chang JT, Wang HM, Liao CT, Kang CJ, Ng SH, et al. [18 F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol. 2006;24:599–604.PubMedView ArticleGoogle Scholar
  10. Chang JT, Chan SC, Yen TC, Liao CT, Lin CY, Lin KJ, et al. Nasopharyngeal carcinoma staging by (18)F-fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2005;62:501–7.PubMedView ArticleGoogle Scholar
  11. Hung TM, Wang HM, Kang CJ, Huang SF, Liao CT, Chan SC, et al. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncol. 2013;49:169–74.PubMedView ArticleGoogle Scholar
  12. Chan SC, Chang JT, Wang HM, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. Oral Oncol. 2009;45:52–8.PubMedView ArticleGoogle Scholar
  13. Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol. 2008;87:211–6.PubMedView ArticleGoogle Scholar
  14. Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, Wang HM. The role of 18 F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. Oral Oncol. 2013;49:71–8.PubMedView ArticleGoogle Scholar
  15. Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18 F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136:883–9.PubMedView ArticleGoogle Scholar
  16. Chang KP, Tsang NM, Liao CT, Hsu CL, Chung MJ, Lo CW, et al. Prognostic significance of 18 F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. J Nucl Med. 2012;53:21–8.PubMedView ArticleGoogle Scholar
  17. Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, et al. Clinical utility of 18 F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. Nucl Med Commun. 2011;32:989–96.PubMedView ArticleGoogle Scholar
  18. Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, et al. Evaluation of intratumoural heterogeneity on 18 F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013;40:685–92.PubMedView ArticleGoogle Scholar
  19. Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT Imaging of Oropharyngeal Squamous Cell Carcinoma: Characteristics of Human Papillomavirus-Positive and -Negative Tumors. Clin Nucl Med. 2013;39:225–31.View ArticleGoogle Scholar
  20. Metz CE. ROC methodology in radiologic imaging. Invest Radiol. 1986;21:720–33.PubMedView ArticleGoogle Scholar
  21. Weissleder R. Molecular imaging in cancer. Science. 2006;312:1168–71.PubMedView ArticleGoogle Scholar
  22. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology. 2007;244:39–47.PubMedView ArticleGoogle Scholar
  23. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006;57:99–118.PubMedView ArticleGoogle Scholar
  24. Jager PL, de Korte MA, Lub-de Hooge MN, van Waarde A, Koopmans KP, Perik PJ, et al. Molecular imaging: what can be used today. Cancer Imaging. 2005;5:S27–32.PubMed CentralPubMedView ArticleGoogle Scholar
  25. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18 F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–300.PubMedView ArticleGoogle Scholar
  26. Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying tumour heterogeneity in 18 F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2013;40:133–40.PubMedView ArticleGoogle Scholar
  27. Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, et al. Intratumor heterogeneity characterized by textural features on baseline 18 F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.PubMed CentralPubMedView ArticleGoogle Scholar
  28. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18 F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26.PubMedView ArticleGoogle Scholar
  29. Vaidya M, Creach KM, Frye J, Dehdashti F, Bradley JD, El Naqa I. Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer. Radiother Oncol. 2012;102:239–45.PubMedView ArticleGoogle Scholar
  30. Watabe T, Tatsumi M, Watabe H, Isohashi K, Kato H, Yanagawa M, et al. Intratumoral heterogeneity of F-18 FDG uptake differentiates between gastrointestinal stromal tumors and abdominal malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26:222–7.PubMedView ArticleGoogle Scholar
  31. El Naqa I, Grigsby P, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recognit. 2009;42:1162–71.PubMed CentralPubMedView ArticleGoogle Scholar
  32. van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–47.PubMed CentralPubMedView ArticleGoogle Scholar
  33. Miwa K, Inubushi M, Wagatsuma K, Nagao M, Murata T, Koyama M, et al. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules. Eur J Radiol. 2014;83:715–9.PubMedView ArticleGoogle Scholar
  34. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13:172–80.PubMedView ArticleGoogle Scholar
  35. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, et al. A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncology. 2012;23:1287–92.View ArticleGoogle Scholar

Copyright

© Yang et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement